1 – 10 of 21
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2021
-
Mark
The influence of domain permutations of an albumin-binding domain-fused her2-targeting affibody-based drug conjugate on tumor cell proliferation and therapy efficacy
(
- Contribution to journal › Article
- 2020
-
Mark
Evaluation of an antibody-PNA conjugate as a clearing agent for antibody-based PNA-mediated radionuclide pretargeting
(
- Contribution to journal › Article
-
Mark
Evaluating the therapeutic efficacy of mono-and bivalent affibody-based fusion proteins targeting HER3 in a pancreatic cancer xenograft model
(
- Contribution to journal › Article
-
Mark
HER2-specific pseudomonas exotoxin a pe25 based fusions : Influence of targeting domain on target binding, toxicity, and in vivo biodistribution
(
- Contribution to journal › Article
- 2016
-
Mark
Increasing the Net Negative Charge by Replacement of DOTA Chelator with DOTAGA Improves the Biodistribution of Radiolabeled Second-Generation Synthetic Affibody Molecules
(
- Contribution to journal › Article
-
Mark
VEGFR2 pY949 signalling regulates adherens junction integrity and metastatic spread
(
- Contribution to journal › Article
- 2015
-
Mark
Site-Specific Radioiodination of HER2-Targeting Affibody Molecules using 4-Iodophenethylmaleimide Decreases Renal Uptake of Radioactivity
(
- Contribution to journal › Article
- 2014
-
Mark
Gallium-68-labeled affibody molecule for PET imaging of PDGFRβ expression in vivo
(
- Contribution to journal › Article
-
Mark
Position for site-specific attachment of a DOTA chelator to synthetic affibody molecules has a different influence on the targeting properties of 68Ga- compared to 111in-labeled conjugates
(
- Contribution to journal › Article
-
Mark
Locally Delivered CD40 Agonist Antibody Accumulates in Secondary Lymphoid Organs and Eradicates Experimental Disseminated Bladder Cancer.
(
- Contribution to journal › Article